Amphastar Pharmaceuticals Total Non-Operating Income/Expense 2012-2024 | AMPH

Amphastar Pharmaceuticals total non-operating income/expense from 2012 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
Amphastar Pharmaceuticals Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $-26
2022 $9
2021 $14
2020 $-6
2019 $60
2018 $-1
2017 $3
2016 $-1
2015 $-3
2014 $-0
2013 $-0
2012 $0
2011 $2
2009 $
Amphastar Pharmaceuticals Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $-9
2024-06-30 $-5
2024-03-31 $-0
2023-12-31 $-13
2023-09-30 $-9
2023-06-30 $-4
2023-03-31 $0
2022-12-31 $3
2022-09-30 $-1
2022-06-30 $-2
2022-03-31 $7
2021-12-31 $3
2021-09-30 $13
2021-06-30 $4
2021-03-31 $-5
2020-12-31 $-10
2020-09-30 $4
2020-06-30 $1
2020-03-31 $-2
2019-12-31 $1
2019-09-30 $-1
2019-06-30 $60
2019-03-31 $-0
2018-12-31 $-1
2018-09-30 $0
2018-06-30 $-1
2018-03-31 $1
2017-12-31 $1
2017-09-30 $1
2017-06-30 $1
2017-03-31 $0
2016-12-31 $-0
2016-09-30 $0
2016-06-30 $-1
2016-03-31 $-0
2015-12-31 $-4
2015-09-30 $-1
2015-06-30 $0
2015-03-31 $1
2014-12-31 $1
2014-09-30 $-0
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $-0
2013-09-30 $0
2013-06-30 $-0
2013-03-31 $-0
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.335B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00